# Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

> **NCT07534371** · — · ACTIVE_NOT_RECRUITING · sponsor: **West China Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** surufatinib
- **DRUG:** Somatostatin Analogs

## Key facts

- **NCT ID:** NCT07534371
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07534371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07534371, "Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07534371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*